Simvastatin with or without ezetimibe in familial hypercholesterolemia.

By J. Kastelein, F. Akdim, E. Stroes, Aeilko H. Zwinderman, M. Bots, A. Stalenhoef, F. Visseren, E. Sijbrands, M. Trip, E. Stein and 5 more. New England Journal of Medicine, 2008

1,138 citations recorded by the source corpus.

Subfields: Cancer Research, Surgery

View Paper: https://www.semanticscholar.org/paper/0da4a48a4d402878a4b01330a3e43a185140f586

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Sekar Kathiresan
2. Arshag D. Mooradian

In Surgery

1. R. Eckel
2. Sekar Kathiresan
3. Arshag D. Mooradian

Citations in the corpus

• Dyslipidemia in type 2 diabetes mellitus (2009, result): “The results of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) tria”
• Validity and reliability of measurement instruments used in research. (2008, result): “Most recently, the Effect of Combination Ezetimibe and High-Dose Simvastatin vs Simvastatin Alone on the Atherosclerotic Process in Subjects with Heterozygous Familial Hypercholesterolemia (ENHANCE) trial found negative results for effects on intima–media thickness, even though the combination of ez”
• Guidelines for the Primary Prevention of Stroke (2011, neutral): “emia, adding ezetimibe to simvastatin did not affect the progression of carotid IMT more than simvastatin alone.(179) In another”
• Carotid intima-media thickness and plaque in cardiovascular risk assessment. (2014, neutral): “90 (11), indicating good test characteristics.”
• Developing medicines that mimic the natural successes of the human genome: lessons from NPC1L1, HMGCR, PCSK9, APOC3, and CETP. (2015, methodology): “progression, as assessed by carotid intima-media thickness (11).”
• The metabolic syndrome. (2008, background): “percholesterolemia despite a 17% lower level of LDL-C (622).”
• Efficacy of statins in familial hypercholesterolaemia: a long term cohort study (2008, background): “In the recently published ENHANCE study, adding ezetimibe to the highest dose of simvastatin resulted in substantial further reductions of LDL cholesterol concentrations and high sensitivity C reactive protein levels but did not further reduce the carotid intima-media thickness.”